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TRAP1, a mitochondrial chaperone with antiapoptotic
functions, is involved in drug-resistance in human CRC.
TRAP1 is a component of the HSP90 mitochondrial
survival pathway, which antagonizes the proapoptotic
activity of cyclophilin D. Interestingly, novel agents are
able to disassemble this pathway and are under clinical
evaluation.
GST-pulldown experiments and mass spectrometry
assays led us to the identification of several TRAP1
ligands and, among others, Sorcin, a Ca
2+-binding pro-
tein involved in the MDR phenotype of human tumors.
We functionally characterized the cooperation between
TRAP1 and Sorcin in favoring survival of CRC cells and
investigated the expression levels of the two proteins in
human CRCs.
We demonstrated the mitochondrial localization of a
18kDa isoform of Sorcin that specifically interacts with
TRAP1 in human CRC cells. The overexpression or
down-regulation of Sorcin and/or TRAP1 allowed us to
demonstrate a reciprocal regulation between the two
proteins and to show that their interaction is required
for Sorcin mitochondrial localization and TRAP1 pro-
tein stability. Furthermore, the upregulation of either
TRAP1 and/or Sorcin induced resistance to 5-fluoruracil
(FU), irinotecan (IRI) and oxaliplatin (l-OHP) in CRC
cells. Of note, the knock-down of TRAP1 and/or Sorcin
expression by siRNAs as well as the pharmacological
inhibition of TRAP1 ATPase re-established a phenotype
sensitive to FU, IRI and l-OHP. Consistently with these
in vitro observations, gene expression analysis showed
that TRAP1 and Sorcin are up-regulated, respectively, in
28/41 and 18/41 CRCs and a significant correlation
between the expression of TRAP1 and the p22 isoform
of Sorcin was observed (Sperman rank test p = 0.003;
Kendal Tau test p = 0.003). Finally, the two proteins are
also co-upregulated in CRC cells resistant to FU, IRI
and l-OHP.
Sorcin and TRAP1 are functionally linked in a survival
network responsible for resistance to chemotherapy in
CRCs. Thus, TRAP1 pathway deserves to be further
evaluated as molecular target to overcome drug resis-
tance in human CRC.
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